13 completed, 6 unknown, 4 terminated, 2 not yet recruiting. 29 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 13, Unknown 6, Terminated 4, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Terminated 1 |
Follow Thrombophilia: new trials by email Literature Review of Thrombophilia trials Research Report on Thrombophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass Human plasma derived antithrombin, Placebo - Acquired Antithrombin Deficiency | Phase 3 | Recruiting | Octapharma | 120 | 2024-08-21 | 2026-09-28 |
| Prolonged Hypercoagulability Following Major Liver Resection for Malignancy Redesca (enoxaparin sodium for injection), Fragmin (dalteparin) - Hepatic Disease, Surgery-Complications | Phase 3 | Not yet recruiting | Western University, Canada | 50 | 2024-06-01 | 2024-04-23 |
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Caplacizumab, Corticosteroids, anti-CD20 antibody - Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 51 | 2022-11-21 | 2025-12-30 |
| Aspirin for Prophylaxis of TTP Aspirin tablet, Placebo - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 100 | 2022-10-01 | 2022-10-05 |
| A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Active not recruiting | Takeda | 77 | 2021-04-14 | 2026-04-02 |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone) - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Completed | Sanofi | 21 | 2019-10-21 | 2025-09-22 |
| Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Sulfate, Magnesium, Placebo - Concentrate - Thrombotic Thrombocytopenic Purpura | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 74 | 2018-05-27 | 2021-10-29 |
| Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation Heparin Sodium, Saline - Sepsis, Disseminated Intravascular Coagulation | Phase 3 | Unknown | China Medical University, China | 600 | 2018-04-12 | 2023-11-18 |
| A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) TAK-755, Standard of care - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Completed | Baxalta now part of Shire | 52 | 2017-10-13 | 2026-02-09 |
| Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) Caplacizumab, Standard of Care - Acquired Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 104 | 2016-10-06 | 2022-03-28 |
| Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Caplacizumab, Placebo - Acquired Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Ablynx, a Sanofi company | 145 | 2015-11-01 | 2023-04-05 |
| The Plasma Large-Volume Exchange RCT Plasma Exchange - Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome | Phase 3 | Withdrawn | London Health Sciences Centre | 2012-04-01 | 2013-04-17 | |
| A Phase 3 Clinical Study of KW-3357 in Patients With DIC KW-3357 - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 5 | 2012-02-01 | 2017-03-24 |
| A Clinical Study of KW-3357 in Patients With DIC KW-3357 - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 15 | 2011-12-01 | 2017-03-24 |
| An Open-label Study of KW-3357 KW-3357, Plasma-derived antithrombin - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 221 | 2011-06-01 | 2017-03-24 |
| Heparin for Pregnant Women With Thrombophilia Nadroparin calcium - Pregnancy and Thrombophilia | Phase 3 | Unknown | Medical University of Vienna | 300 | 2010-01-01 | 2009-11-25 |
| Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Isoflavone, Placebo - Menopause | Phase 3 | Unknown | Federal University of São Paulo | 84 | 2009-08-01 | 2009-06-22 |
| Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Rituximab, Plasma exchange, Corticosteroids - Thrombotic Thrombocytopenic Purpura | Phase 3 | Terminated | Carelon Research | 3 | 2009-04-01 | 2013-07-22 |
| ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Clopidogrel+acetylsalicylic acid, acetylsalicylic acid - Graft Patency, Coronary Artery Bypass Grafting Surgery | Phase 3 | Unknown | Copenhagen University Hospital, Rigshospitalet | 250 | 2008-11-01 | 2013-09-24 |
Showing 20 of 29. Sign in to see all of them.
Purpura, Thrombotic Thrombocytopenic (12) · Antithrombin III Deficiency (4) · Disseminated Intravascular Coagulation (4) · Thrombosis (3) · Hemostatic Disorders (2) · Pre-Eclampsia (2) · Venous Thromboembolism (2) · Venous Thrombosis (2) · Abortion, Habitual (1) · Abortion, Spontaneous (1) · Digestive System Diseases (1) · Hematologic Diseases (1) · Hemolytic-Uremic Syndrome (1) · Postpartum Hemorrhage (1)
Hemic and Lymphatic Diseases (29) · Hematologic Diseases (28) · Blood Coagulation Disorders (21) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Hemorrhage (13) · Blood Platelet Disorders (12) · Cytopenia (12) · Purpura (12) · Purpura, Thrombocytopenic (12) · Signs and Symptoms (12) · Skin Manifestations (12) · Thrombocytopenia (12) · Thrombotic Microangiopathies (12)
Aspirin (4) · caplacizumab (4) · Dalteparin (3) · Plasma Exchange (3) · Rituximab (3) · ADAMTS13 protein, human (2) · Adrenal Cortex Hormones (2) · Nadroparin (2) · Prednisolone (2) · Prednisone (2) · Standard of Care (2) · Biosimilar Pharmaceuticals (1) · Clopidogrel (1) · Cyclosporine (1) · Enoxaparin (1)
Kyowa Kirin Co., Ltd. (3) · Sanofi (3) · Baxalta now part of Shire (2) · Octapharma (2) · rEVO Biologics (2) · Ablynx, a Sanofi company (1) · Assistance Publique - Hôpitaux de Paris (1) · Carelon Research (1) · China Medical University, China (1) · Copenhagen University Hospital, Rigshospitalet (1) · Federal University of São Paulo (1) · Instituto Grifols, S.A. (1) · London Health Sciences Centre (1) · Medical University of Vienna (1) · Ohio State University (1)
United States (13) · France (10) · Canada (9) · United Kingdom (8) · Austria (7) · Germany (7) · Italy (7) · Japan (7) · Spain (5) · Belgium (4) · Czechia (4) · Netherlands (3) · Poland (3) · Switzerland (3) · Australia (2)
Anton Skaro, MD PhD (1) · Barbara Konkle, MD (1) · Bernd Poetzsch, Professor (1) · Cambell Tait, MD (1) · Christopher Hillyer, MD (1) · Cindy Leissinger, MD (1) · Clemens B Tempfer, MD (1) · Darrell Triulzi, MD (1) · David Kuter, MD (1) · Eliot Williams, MD, PhD (1) · Ellis Neufeld, MD (1) · James Bussel, MD (1)
PMID 22449204, PMID 24335249, PMID 33779986, PMID 22540524, PMID 25066248, PMID 29296854, PMID 30473794, PMID 30625070, PMID 31691462, PMID 32358837, PMID 33881463, PMID 36138517, PMID 36427162, PMID 38167115, PMID 38692292, PMID 39095866, PMID 41348038
2015 (1), 2016 (1), 2017 (1), U01HL072268 (1)